Is the worst behind for Natural Capsules (NSE: NATCAPSUQ) after API delays and US tariff headwinds?

Natural Capsules Limited, one of India’s leading hard capsule manufacturers and a pioneer in vegetarian capsule production, posted a challenging second quarter for FY26 marked by weakening margins, delayed API commercialization, and tariff headwinds from the United States. The company reported a consolidated revenue of ₹45.8 crore for the quarter ended September 30, 2025, showing a modest 1.33 percent sequential increase. However, profitability metrics sharply deteriorated, with EBITDA slipping into negative territory at ₹0.88 crore and the net loss widening to ₹6.99 crore from ₹5.58 crore in the previous quarter. Year-on-year, the net loss ballooned by over 1,000 percent, reflecting multiple structural and cyclical hurdles in the company’s dual-pronged growth engines.

Why did Natural Capsules’ capsule segment face margin pressure despite steady revenue growth?

The capsule segment, historically the company’s core revenue generator, experienced steady demand in the domestic market. But growth momentum from hydroxypropyl methylcellulose (HPMC) capsules was disrupted as the United States imposed a steep tariff differential between Indian and Chinese imports. Indian HPMC capsules now attract a 14 percent import duty, while Chinese capsules face an 88 percent tariff. While this should have translated into a near-term competitive tailwind for Indian exporters, the reality appears more complex. The American pharmaceutical import ecosystem has responded with caution, leading to slower purchase decisions and hesitation in switching suppliers despite the pricing advantage. Natural Capsules Limited, heavily reliant on its growing HPMC capacity for margin accretion, saw its US business falter during this transition window.

Sunil Mundra, Managing Director of Natural Capsules Limited, noted in his commentary that were it not for the US tariff disruption, the company would likely have delivered stronger revenue and healthier margins in Q2. He added that the capital expenditure program to commission a new HPMC production line is progressing on schedule and is expected to be completed by the end of the third quarter. Once the current market distortion stabilizes and importers regain confidence, the company anticipates a pick-up in HPMC exports. The broader capsule business remains operationally stable, supported by long-term clients across regulated and unregulated markets in North America, South America, and Africa.

How are fermentation scale-up issues delaying API commercialization at Tumkur despite regulatory approvals?

While the capsule business contends with demand-side friction, the active pharmaceutical ingredient (API) vertical is grappling with execution complexity. Natural Capsules Limited has ventured into the steroidal API market under its subsidiary Natural Biogenex Private Limited. This strategic diversification has been underpinned by a ₹67 crore Production Linked Incentive (PLI) commitment awarded by the Government of India, making the company one of the only domestic manufacturers of Dexamethasone and Betamethasone and one of two producers of Prednisolone. Despite receiving the necessary environmental clearances from the Pollution Control Board, the company faced technical challenges in scaling fermentation batches from lab to commercial scale. Fermentation-driven synthesis, particularly for steroidal APIs, is known for its high process sensitivity and often encounters bottlenecks during scale-up phases.

The Tumkur API facility is India’s first integrated steroidal API plant using a combination of fermentation and synthesis reactions. It is being developed to meet compliance standards aligned with WHO GMP, USFDA, and EU GMP norms. Natural Capsules Limited aims to position itself as a backward-integrated domestic supplier at a time when India continues to reduce its dependency on API imports. In FY25 alone, India imported over ₹176 crore worth of Prednisolone and ₹179 crore worth of Betamethasone, and Natural Capsules Limited believes it can gradually substitute a significant share of this demand through its new plant.

How do Natural Capsules’ H1FY26 numbers illustrate rising operating costs, shrinking liquidity and a margin trajectory that may pressure recovery in the next few quarters?

The consolidated financials for the first half of FY26 underscore the pressure on both earnings and balance sheet health. Revenue for H1FY26 came in at ₹91.01 crore, up 13.18 percent year-on-year, while EBITDA margins contracted sharply into the red at minus 0.62 percent. The company reported a loss of ₹12.57 crore for the six-month period, a steep fall from near break-even in the comparable period of FY25. Operating expenses surged 28 percent year-on-year, indicating that cost pressures are outpacing revenue growth. Depreciation and finance costs rose by over 80 percent and 60 percent respectively, reflecting the strain of ongoing capital investments and increased debt servicing.

On the balance sheet, equity declined from ₹257.16 crore at the end of FY25 to ₹245.40 crore as of September 30, 2025. Current liabilities increased to ₹110.01 crore, and net cash from operations for H1FY26 stood at ₹5.41 crore, down from ₹12.01 crore in H1FY25. Net cash flow for the period was a negligible ₹0.07 crore, with closing cash and equivalents at just ₹0.76 crore. The margin erosion and limited liquidity buffer raise questions about the company’s short-term financial flexibility, although long-term structural drivers remain intact.

How is Natural Capsules aligning its capsules and API segments to pursue global expansion and regulatory growth?

Despite this weak quarterly performance, Natural Capsules Limited continues to pursue its broader strategic roadmap. The company is focused on ramping up its presence in regulated capsule markets, supported by marquee pharma clients and efforts to introduce specialty capsule variants such as fast-release, preservative-free, and sweet capsules. New-generation high-speed capsule manufacturing machines, including the one installed in FY25, are expected to drive productivity and yield improvements. Management is also exploring global expansion options, including setting up overseas manufacturing units to improve responsiveness and reduce lead times for international customers.

On the API front, the company’s efforts are closely aligned with government incentives and national self-reliance objectives. The ₹67 crore PLI cushion significantly de-risks its API capex investments. The incentive structure is frontloaded, with 20 percent sales-linked benefits available from FY25 to FY28, declining to 15 percent and 10 percent in subsequent years. This offers a meaningful buffer against early-stage commercialization volatility. Analysts believe that once fermentation issues are resolved and regulatory compliance is fully achieved, the API vertical could become a margin-accretive engine for Natural Capsules Limited.

What signals will investors, analysts and institutional trackers focus on over the next two quarters as Natural Capsules navigates tariff disruptions and API scale‑up delays?

Investor sentiment remains cautious in the near term. The company’s shares fell 5 percent intraday on November 14, 2025, following the earnings announcement, closing at ₹203.87. Market participants are expected to monitor two near-term developments: commissioning of the new HPMC capsule line and successful fermentation scale-up in the API plant. These events could serve as catalysts to restore operating leverage and reignite confidence in the stock.

For now, Natural Capsules Limited must navigate the dual challenge of navigating external policy headwinds in its capsule export business and resolving internal execution issues in its API manufacturing unit. With PLI backing, a credible history of product innovation, and investments in capacity and compliance, the company appears structurally well-placed, even if tactically constrained. The next two quarters will likely determine whether the current downturn is a temporary detour or signals a more prolonged reset in the company’s earnings trajectory.

Key takeaways from Natural Capsules’ Q2 and H1FY26 results and strategic outlook

• Natural Capsules Limited reported Q2FY26 consolidated revenue of ₹45.8 crore, up 1.33 percent sequentially and 11.11 percent year-on-year.
• The company posted a net loss of ₹6.99 crore for Q2, marking a 25.24 percent decline over Q1FY26, with EBITDA slipping into negative territory at ₹0.88 crore.
• Half-year consolidated revenue reached ₹91.01 crore, up 13.18 percent year-on-year, but net loss widened to ₹12.57 crore.
• Operating margin turned negative at –0.62 percent in H1FY26, down from 11.03 percent in H1FY25, reflecting high input costs and fixed operating leverage stress.
• HPMC capsule exports to the United States were disrupted due to new import tariffs, weighing on growth and profitability in the capsules division.
• The company’s new HPMC line is expected to be commissioned by the end of Q3FY26, positioning it to recapture volume growth once trade conditions stabilize.
• Fermentation scale-up challenges delayed the start of commercial production at the company’s steroidal API facility in Tumkur, which is backed by ₹67 crore in Production Linked Incentive support.
• The Tumkur plant is India’s first integrated fermentation-and-synthesis-based API unit for Dexamethasone, Betamethasone, and Prednisolone.
• Cash flow from operations dropped to ₹5.41 crore in H1FY26 from ₹12.01 crore a year earlier, while cash reserves declined to ₹0.76 crore, raising short-term liquidity concerns.
• Institutional investors are closely monitoring the HPMC ramp-up and fermentation stabilization as potential catalysts for a recovery in margin and sentiment over the next two quarters.